Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, Dok Hyunyoon, Ho Jin Shin, Yeung Chul Mun, Yong Park, Young Rok Do, Seong Hyun Jeong, Joon Seong Park, Sung Yong Oh, Suee Lee, Eun Kyung Park, Joung Soon Jang, Won Sik Lee, Hwe Won Lee, Hyeonseok Eom, Jae Sook Ahn, Jae Heon Jeong, Sun Kyung BaekSeok Jin Kim, Won Seog Kim, Cheolwon Suh

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. Methods: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. Results: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). Conclusions: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.

Original languageEnglish
Article number49
JournalJournal of Hematology and Oncology
Volume5
DOIs
Publication statusPublished - 2012 Aug 15

    Fingerprint

Keywords

  • Diffuse large B-cell lymphoma
  • Primary adrenal lymphoma
  • Prognostic factor
  • R-CHOP

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Kim, Y. R., Kim, J. S., Min, Y. H., Hyunyoon, D., Shin, H. J., Mun, Y. C., Park, Y., Do, Y. R., Jeong, S. H., Park, J. S., Oh, S. Y., Lee, S., Park, E. K., Jang, J. S., Lee, W. S., Lee, H. W., Eom, H., Ahn, J. S., Jeong, J. H., ... Suh, C. (2012). Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). Journal of Hematology and Oncology, 5, [49]. https://doi.org/10.1186/1756-8722-5-49